MINDCURE Names Tarik Lebbadi as Chief Operating Officer

MINDCURE’s new COO, Tarik Lebbadi, recently led an international division of Johnson & Johnson.

Read more

Scientists have used advanced computer simulations to better understand the neurobiological mechanisms underlying the psychedelic experience.

Read more
How Analysts Are Asleep At The Wheel Regarding Psychedelic Stocks

Psychedelic drug stocks represent (by far) the best new opportunity in life sciences today. Institutional capital is flooding into the sector. But market analysts are asleep-at-the-wheel here.

Read more
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology

MINDCURE adds a new tech specialist to direct the development of its iSTRYM R&D platform.

Read more
Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader in Distribution of Psychedelics

Red Light Holland acquires a Netherlands distributor of psilocybin-based products.

Read more
Numinus Announces Closing of $40-Million Bought Deal Financing

Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.

Read more

The use of psychedelic substances is associated with better physical health, according to preliminary research published in the Journal of Psychopharmacology.

Read more
D.C. Psychedelics Decriminalization Initiative Officially Takes Effect

A wide range of psychedelics such as psilocybin and ayahuasca are now officially the lowest local law enforcement in the nation’s capital as of Monday.

Read more
Psychedelic Drug Development Or Clinics: Which Is The Better Path To Investor Profits?

Drug development or mental health clinics? We explore the benefits of both business strategies for investors in psychedelic stocks.

Read more
Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing

Field Trip closes on a CAD$95 million bought deal financing, nearly double the original CAD$50 million offering.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )